Compare SBSI & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | KALV |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 1.0B |
| IPO Year | 1995 | 2014 |
| Metric | SBSI | KALV |
|---|---|---|
| Price | $33.15 | $26.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $35.33 | $32.60 |
| AVG Volume (30 Days) | 58.2K | ★ 2.8M |
| Earning Date | 04-30-2026 | 07-09-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $28.87 | $185.42 |
| Revenue Next Year | $5.82 | $59.23 |
| P/E Ratio | $42.22 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $26.32 | $9.83 |
| 52 Week High | $34.53 | $26.98 |
| Indicator | SBSI | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 75.23 |
| Support Level | $31.73 | $14.22 |
| Resistance Level | $34.22 | N/A |
| Average True Range (ATR) | 0.72 | 0.05 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 85.77 | 87.04 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.